Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, has announced the approval of equity inducement grants for seven new non-officer employees. The grants, approved by the company's Compensation Committee, consist of 53,550 share options with an exercise price of $29.04 per common share, reflecting the closing price on May 29, 2025. These options are part of the company's 2025 Inducement Equity Incentive Plan and will vest over four years: 25% on the first anniversary of the employee's start date, with the remainder vesting monthly over the subsequent three years. The options have a 10-year term.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。